NGNE – neurogene inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

NGNE

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

4/14

08:09 am

ngne

Neurogene Inc. (NASDAQ: NGNE) had its price target lowered by analysts at BMO Capital Markets from $45.00 to $16.00. They now have an "outperform" rating on the stock.

Medium Report

Neurogene Inc. (NASDAQ: NGNE) had its price target lowered by analysts at BMO Capital Markets from $45.00 to $16.00. They now have an "outperform" rating on the stock.

Report

4/7

10:03 am

ngne

Neurogene Inc. (NASDAQ: NGNE) was given a new $38.00 price target on by analysts at Robert W. Baird.

Low Report

Neurogene Inc. (NASDAQ: NGNE) was given a new $38.00 price target on by analysts at Robert W. Baird.

Report

4/2

04:17 pm

ngne

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome [Yahoo! Finance]

High Report

Report

4/2

04:01 pm

ngne

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

Medium Report

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

Report

3/25

12:18 pm

ngne

Neurogene Inc. (NASDAQ: NGNE) had its "outperform" rating re-affirmed by analysts at William Blair.

Medium Report

Neurogene Inc. (NASDAQ: NGNE) had its "outperform" rating re-affirmed by analysts at William Blair.

Report

3/25

08:17 am

ngne

Neurogene Inc. (NASDAQ: NGNE) had its price target lowered by analysts at HC Wainwright from $55.00 to $50.00. They now have a "buy" rating on the stock.

Low Report

Neurogene Inc. (NASDAQ: NGNE) had its price target lowered by analysts at HC Wainwright from $55.00 to $50.00. They now have a "buy" rating on the stock.

Report

3/24

04:26 pm

ngne

Neurogene Inc. (NGNE) Stock [Seeking Alpha]

Low Report

Neurogene Inc. (NGNE) Stock [Seeking Alpha]

Report

3/24

04:19 pm

ngne

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates [Yahoo! Finance]

Low Report

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates [Yahoo! Finance]

Report

3/24

04:10 pm

ngne

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates

Low Report

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates

Report

2/26

09:09 am

ngne

MAAST DIGITAL Unveils AI-Powered ERMA Evaluate™: A Revolutionary Platform Set to Transform the Traditional Medical, Legal and Regulatory Review Process for Life Science Companies [Yahoo! Finance]

Low Report

MAAST DIGITAL Unveils AI-Powered ERMA Evaluate™: A Revolutionary Platform Set to Transform the Traditional Medical, Legal and Regulatory Review Process for Life Science Companies [Yahoo! Finance]

Report

2/24

07:30 am

ngne

Neurogene to Participate in Upcoming Conferences

Medium Report

Neurogene to Participate in Upcoming Conferences

Report

2/16

07:15 am

ngne

Neurogene Insiders Placed Bullish Bets Worth US$1.46m [Yahoo! Finance]

Low Report

Neurogene Insiders Placed Bullish Bets Worth US$1.46m [Yahoo! Finance]

Report

2/4

05:20 pm

ngne

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

High Report

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

Report

2/1

10:00 am

ngne